HC Wainwright Has Bullish Estimate for ADVM Q3 Earnings

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) – HC Wainwright upped their Q3 2025 earnings estimates for Adverum Biotechnologies in a research note issued to investors on Wednesday, August 13th. HC Wainwright analyst M. Caufield now anticipates that the biotechnology company will earn ($0.84) per share for the quarter, up from their previous forecast of ($1.19). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Adverum Biotechnologies’ current full-year earnings is ($4.92) per share. HC Wainwright also issued estimates for Adverum Biotechnologies’ Q4 2025 earnings at ($0.83) EPS, FY2025 earnings at ($4.87) EPS, FY2026 earnings at ($3.21) EPS, FY2027 earnings at ($3.22) EPS, FY2028 earnings at ($2.99) EPS and FY2029 earnings at ($2.12) EPS.

Adverum Biotechnologies (NASDAQ:ADVM) last announced its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($2.34) earnings per share for the quarter, missing the consensus estimate of ($2.24) by ($0.10).

Several other equities analysts have also weighed in on ADVM. Mizuho cut their price objective on shares of Adverum Biotechnologies from $16.00 to $12.00 and set an “outperform” rating on the stock in a report on Thursday, June 26th. Chardan Capital restated a “buy” rating and issued a $33.00 price objective on shares of Adverum Biotechnologies in a report on Wednesday. Finally, Royal Bank Of Canada cut their target price on shares of Adverum Biotechnologies from $5.00 to $4.00 and set a “sector perform” rating on the stock in a report on Thursday, May 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Adverum Biotechnologies presently has an average rating of “Hold” and an average price target of $19.75.

Adverum Biotechnologies Price Performance

Shares of NASDAQ ADVM opened at $2.86 on Friday. The company’s 50 day simple moving average is $2.52 and its 200 day simple moving average is $3.26. Adverum Biotechnologies has a fifty-two week low of $1.78 and a fifty-two week high of $8.56. The firm has a market capitalization of $60.00 million, a P/E ratio of -0.36 and a beta of 0.77.

Institutional Investors Weigh In On Adverum Biotechnologies

Large investors have recently made changes to their positions in the stock. Wells Fargo & Company MN increased its position in shares of Adverum Biotechnologies by 27.8% during the fourth quarter. Wells Fargo & Company MN now owns 12,240 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 2,659 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in Adverum Biotechnologies in the second quarter valued at $45,000. XTX Topco Ltd bought a new position in Adverum Biotechnologies in the second quarter valued at $64,000. JPMorgan Chase & Co. grew its position in Adverum Biotechnologies by 226.6% in the fourth quarter. JPMorgan Chase & Co. now owns 30,664 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 21,274 shares in the last quarter. Finally, Qube Research & Technologies Ltd bought a new position in Adverum Biotechnologies in the second quarter valued at $66,000. Institutional investors own 48.17% of the company’s stock.

Adverum Biotechnologies Company Profile

Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.